Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel anti-human ctgf antibody

A technology of antibodies and antibody fragments, applied in the direction of antibodies, anti-animal/human immunoglobulins, animal/human proteins, etc., can solve the problems that CTGF neutralizing activity is not strong enough, binding activity is not sufficient, etc., to achieve Effects of improved treatment effectiveness and patient compliance, improved dosing method, and extended dosing intervals

Active Publication Date: 2017-03-08
ASTELLAS PHARMA INC
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, the binding activity of conventional antibodies to CTGF is not sufficient, and the neutralizing activity to CTGF is not strong enough from the viewpoint of therapeutic effectiveness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel anti-human ctgf antibody
  • Novel anti-human ctgf antibody
  • Novel anti-human ctgf antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] (Example 1: the acquisition of CTGF protein from various sources)

[0093]The present inventors obtained human CTGF protein as an antigen for making anti-CTGF antibodies. The full-length gene (sequence number 13) of human CTGF is integrated in the expression vector (pcDNA3.1; Invitrogen Company), the vector that will be made uses FreeStyle MAX Reagent (Invitrogen Company) as gene transfer reagent to FreeStyle293 cell (Invitrogen Company) ) for gene transfer. The cells were cultured in a serum-free culture system using FreeStyle293 expression medium (Invitrogen) to obtain a culture supernatant containing human CTGF protein. Proteins were purified from the obtained culture supernatants using HiTrap heparin columns and CM columns (GE Healthcare Japan), and used for the following experiments. For mouse, rat and monkey CTGF proteins, the same method was used to obtain them.

Embodiment 2

[0094] (Example 2: Immunization to VelocImmune mice)

[0095] Anti-human CTGF antibody was obtained by immunizing VelocImmune mice. In order to increase the diversity of the antibodies obtained, the present inventors conducted research on various immunization methods, administration routes, adjuvants, immunization periods, and the like. As an immunogen, purified human CTGF was used and mixed with an adjuvant for immunization. As the route of administration, plantar administration and intraperitoneal administration were investigated. As an adjuvant, TiterMax Gold (CytRx), complete Freund's adjuvant (Sigma), and incomplete Freund's adjuvant (Sigma) were investigated. As further added immune stimulators, CpG oligonucleotides and aluminum phosphate gel (BRENNTAG) were investigated. As the immunization period, 3 weeks to 14 weeks were studied. After several immunizations, blood was collected from the tail vein of the mice, and the titer was monitored to select VelocImmune mice ...

Embodiment 3

[0097] (Example 3: Production of hybridomas producing anti-human CTGF antibodies)

[0098] Final immunization (intravenous or intraperitoneal administration of the antigen) was performed on mice selected after confirming the increase in antibody titer. According to a conventional method, the spleen, lymph nodes, etc. of the immunized mice were removed, lymphocytes were collected, and they were fused with mouse myeloma cells SP2 / 0 to prepare hybridomas. The hybridomas were subjected to limiting dilution, and on the basis of obtaining single clones, antibodies were purified from the supernatant using a protein A or protein G column (GE Healthcare Japan).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An object of the present invention is to provide an anti-human CTGF antibody having excellent binding activity and / or neutralizing activity, as compared with conventional anti-human CTGF antibodies, and means for preventing or treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy, using the anti-human CTGF antibody. [Means for Solution] An anti-human CTGF antibody includes: a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 10; and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 4.

Description

technical field [0001] The present invention relates to novel anti-human CTGF antibodies. Specifically, the novel anti-human CTGF antibody of the present invention is an anti-human CTGF antibody superior in binding activity and / or neutralizing activity to conventional anti-human CTGF antibodies. Background technique [0002] CTGF (connective tissue growth factor) is a secreted protein with a molecular weight of about 36 to 38 kDa and rich in cysteine ​​residues belonging to the CCN family (Non-Patent Document 1). TGF-β induction of growth factor (Non-Patent Document 2). Therefore, it is speculated that TGF-β induces CTGF, and the induced CTGF promotes the fibrosis of organs and tissues. CTGF is considered to play an important role in fibrosis, cell proliferation, metabolism of extracellular matrix, angiogenesis, arteriosclerosis, etc. Patent Document 3). [0003] Multiple domains are known to exist in CTGF and interact with other factors. Among them, it has been revealed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/09C07K16/22C12N1/15C12N1/19C12N1/21C12N5/10C12N15/02C12P21/08
CPCA61K2039/505A61P13/12C07K14/475C07K16/22C07K2317/24C07K2317/41C07K2317/92C07K2317/76
Inventor 岩崎正司守屋隆一吉野正康高仓浩二
Owner ASTELLAS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com